Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Infinity Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2001
Status: Out of Business
BioCentury | Jul 26, 2023
Finance
July 26 Quick Takes: Versant’s Nexo launches with $60M series A round
Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
BioCentury | Mar 24, 2023
Finance
Who’s gone? A snapshot of biotechs closing doors
Biotech struck by a wave of downsizing, restructuring and closures, as companies run out of options in an unforgiving market
BioCentury | Jul 21, 2022
Management Tracks
Versanis recruits Pruzanski as CEO, adds Maraganore, Duncan to board
Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Feb 11, 2022
Management Tracks
Silberstein joins GentiBio as CFO
Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Sep 9, 2021
Management Tracks
Hayes joins Fulcrum as chief commercial officer
Plus: ImmunityBio, Finch, Rhythm, Infinity, Locanabio and more
BioCentury | Jan 27, 2021
Emerging Company Profile
Nuvalent: Structure-based design to address selectivity, tumor resistance
Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic
BioCentury | Mar 21, 2020
Management Tracks
Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc
BioCentury | Jan 29, 2020
Product Development
Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO
Laurence Reid succeeds Steven Holtzman as Decibel sharpens focus of early R&D
BioCentury | Sep 16, 2019
Company News
Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian
Items per page:
1 - 10 of 294